Irene Ghobrial, M.D., is trying to identify what causes myeloma cells to become drug resistant. She is also leading research to try to understand how to treat premalignant conditions like monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma before they become the more deadly acute myeloid leukemia and myeloma, respectively. Dr. Ghobrial, along with DFCI’s Robert Soiffer, M.D., also leads LLS and DFCI’s collaboration through LLS’s Therapy Acceleration Program to bring clinical trials to local community cancer centers. Dr. Ghobrial currently leads an LLS Specialized Center of Research (SCOR) grant, and also has a Translational Research Program grant.
Director, Michele & Stephen Kirsch Lab, Dana-Farber Cancer Institute